
Effective stewardship of novel gram-negative agents pairs restriction with deliberate promotion of timely empiric use in high-risk patients, keeping optimized outcomes, rather than limitation, as the central goal.
Tamma is associate professor of Pediatrics in the Division of Pediatric Infectious Diseases at The Johns Hopkins University School of Medicine.

Effective stewardship of novel gram-negative agents pairs restriction with deliberate promotion of timely empiric use in high-risk patients, keeping optimized outcomes, rather than limitation, as the central goal.

Early collaboration with microbiology laboratories, reflex testing algorithms, and mechanism-based teaching help ensure that new antimicrobials reach the right patients and that resistance results are interpreted correctly.

Securing formulary access to novel gram-negative agents depends on local epidemiology, outcome data, and electronic order safeguards, communicated clearly to committees that often lack infectious diseases expertise.

Cefiderocol's first-line recommendation for Stenotrophomonas maltophilia rests on compelling preclinical data that historic agents lack, but sparse clinical evidence supports initial combination therapy in critically ill patients.

After distinguishing true infection from colonization, the updated guidance positions sulbactam-durlobactam combined with a carbapenem as the clearly preferred regimen for carbapenem-resistant Acinetobacter baumannii.

Because multiple overlapping mechanisms drive resistance in Pseudomonas aeruginosa, clinicians must test every relevant novel agent, with ceftolozane-tazobactam favored for difficult-to-treat resistant pneumonia.

Ceftazidime-avibactam and meropenem-vaborbactam remain reliable options for KPC producers, ceftazidime-avibactam is favored for OXA-48-like enzymes, and the US withdrawal of imipenem-relebactam narrows the available choices.

Cefepime-zidebactam pairs a familiar cephalosporin with a beta-lactam enhancer that targets a second penicillin-binding protein, producing encouraging preclinical activity against carbapenem-resistant organisms ahead of clinical availability.

Penicillin-binding protein 3 alterations in NDM-producing E. coli can compromise both aztreonam-avibactam and cefiderocol simultaneously, while tetracycline derivatives retain a narrow role in carefully selected scenarios.

In critically ill patients receiving continuous renal replacement therapy, aggressive early dosing guided by effluent rate and close pharmacist partnership helps protect drug exposure when MICs already approach the breakpoint.

Elevated MICs, NDM-mediated hydrolysis, and a concerning clinical mortality signal have prompted experts to question whether cefiderocol warrants equal standing with aztreonam-avibactam for NDM-producing Enterobacterales.

Aztreonam-avibactam pairs a monobactam spared by NDM with an inhibitor of its companion enzymes, offering optimized pharmacodynamics and simpler administration, though NDM-specific clinical data remain limited.

NDM has diversified and disseminated faster than any prior carbapenemase through mobile genetic elements and distinctive enzyme properties, yet KPC persists, requiring clinicians to account for both in therapeutic planning.

Rapid molecular testing from positive blood cultures delivers actionable resistance data within hours, and knowing when each result arrives, and which are suppressed, shortens the time to effective therapy.

Empiric use of novel agents should follow patient-level risk and unit-level epidemiology, while a shared vocabulary for carbapenem-resistant Enterobacterales and their carbapenemases underpins every subsequent treatment decision.

Overall gram-negative resistance rates have plateaued, but the carbapenemases driving carbapenem resistance have shifted, with NDM expanding alongside KPC and reshaping treatment considerations across the Enterobacterales.

In the sixth and final episode, the clinicians unpack the most debated change in the guidance, the move to cefiderocol monotherapy as the preferred option for invasive S maltophilia infections, and invite community feedback.

In part 5 of the series, the clinicians explain the shift toward sulbactam-durlobactam for invasive carbapenem-resistant Acinetobacter baumannii infections and how hospitals with low CRAB volume can still plan for access.

In the fourth episode of a 6-part series, the clinicians compare agents for DTR P aeruginosa and explain why local antibiogram data should guide empiric choices.

In the third episode, the clinicians compare aztreonam-avibactam with cefiderocol for NDM-producing Enterobacterales, weigh formulary needs against local epidemiology, and discuss stewardship planning for emerging agents.

In part 2 of a 6-part series, the clinicians explain why the 2026 guidance now organizes CRE treatment by carbapenemase type and why meropenem-vaborbactam earned a slight edge for KPC producers.

This is the first in a series of discussions between medical peers on the 2026 IDSA guidance for antimicrobial-resistant gram-negative infections, beginning with current clinical challenges and new options for ESBL- and AmpC-producing organisms.

Panelists discuss the urgent need to ensure equitable access to novel antibiotics, highlighting global and domestic disparities, the vital role of stewardship programs, and the importance of innovative distribution models, international collaboration, and systemic reforms to bring lifesaving treatments to resource-limited settings.

Panelists discuss the complex, systemwide stewardship considerations for incorporating new antibiotics targeting resistant pathogens, emphasizing the need for real-world efficacy data, thoughtful formulary restrictions, and tailored strategies for outpatient use to ensure safe, effective, and sustainable adoption across diverse care settings.

Panelists discuss how regulatory incentives are advancing antimicrobial development, enabling a shift away from older, toxic agents like colistin, while acknowledging that despite the superiority of newer therapies, polymyxins still retain a limited role in rare, highly resistant infections where no better alternatives exist.

Panelists discuss how the clinical use of new antibiotics often extends beyond US Food and Drug Administration (FDA)–approved indications, driven by microbiological activity and clinical judgment, while highlighting the role of regulatory incentives like Qualified Infectious Disease Product (QIDP) in accelerating drug development and the need for careful, collaborative interpretation of limited trial data to ensure responsible off-label use.

Panelists discuss the challenges of implementing susceptibility testing for new antibiotics, emphasizing the need for close lab-clinician collaboration, streamlined reflex testing protocols, and investment in diagnostic infrastructure to ensure timely and effective treatment of multidrug-resistant infections.

Panelists discuss the evolving landscape of novel antibiotic combinations targeting metallo-β-lactamase (MBL)–producing and other multidrug-resistant Gram-negative bacteria, emphasizing promising early data despite limited clinical trials, the complexity of resistance mechanisms, and the potential for these therapies to improve outcomes and shape future treatment strategies.

Panelists discuss the innovative use of the aztreonam-avibactam combination to combat complex β-lactamase–mediated resistance, highlighting promising laboratory data, challenges in clinical trial enrollment for resistant infections, and the ongoing need for further research to define its role in treating multidrug-resistant Gram-negative pathogens.

Panelists discuss the real-world challenges of managing infections caused by highly resistant organisms, highlighting the impact of limited access to novel diagnostics and therapeutics, the complexities of outpatient treatment, and the urgent need for broader-spectrum agents and improved delivery methods in resource-constrained settings.

September 12th 2025